Halozyme Therapeutics (HALO)
124.83
+0.46 (0.37%)
Upcoming Events
Latest Headlines
H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)
October 16, 2026 6:56 AM - StreetInsider
Russell Investments Canada Limited Announces Monthly Distributions for Exchange Traded Fund Series (“ETF Series”) and Exchange Traded Funds (“ETFs”)
October 13, 2026 4:00 PM - BizWire
Halozyme Therapeutics (HALO) PT Raised to $130 at TD Cowen
October 13, 2026 9:39 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)
October 13, 2026 6:47 AM - StreetInsider
Form 4 HALOZYME THERAPEUTICS, For: Oct 06 Filed by: Torley Helen
October 8, 2026 7:56 PM - SEC Filing
Form 4/A HALOZYME THERAPEUTICS, For: May 05 Filed by: Connaughton Bernadette
October 8, 2026 7:55 PM - SEC Filing
Halozyme Therapeutics (HALO) PT Raised to $78 at JPMorgan
October 8, 2026 8:09 AM - StreetInsider
Halozyme stock rises after winning injunction against Merck
October 7, 2026 11:37 AM - StreetInsider
Dutch court orders Merck to halt Keytruda SC sales in 8 countries
October 7, 2026 8:30 AM - StreetInsider
Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets
October 7, 2026 8:30 AM - PR NewsWire
H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)
October 7, 2026 6:49 AM - StreetInsider
Halozyme expands argenx deal to cover two more drug targets
October 6, 2026 4:05 PM - StreetInsider
Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE®
October 6, 2026 4:05 PM - PR NewsWire
Form 4 HALOZYME THERAPEUTICS, For: Oct 01 Filed by: Daly James M
October 2, 2026 4:44 PM - SEC Filing
Form 3 HALOZYME THERAPEUTICS, For: Sep 28 Filed by: Daly James M
October 2, 2026 4:41 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: Oct 01 Filed by: Posard Matthew L.
October 2, 2026 4:38 PM - SEC Filing
Form 8-K HALOZYME THERAPEUTICS, For: Sep 28
September 30, 2026 4:20 PM - SEC Filing
Halozyme adds Jim Daly to its board of directors
September 30, 2026 4:05 PM - StreetInsider
Halozyme Announces Appointment of Jim Daly to its Board of Directors
September 30, 2026 4:05 PM - PR NewsWire
Form 8-K HALOZYME THERAPEUTICS, For: Sep 22
September 22, 2026 4:41 PM - SEC Filing
Form 8-K HALOZYME THERAPEUTICS, For: Sep 17
September 18, 2026 8:23 AM - SEC Filing
Halozyme prices $1.3B convertible notes offering due 2033
September 17, 2026 11:20 PM - StreetInsider
Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033
September 17, 2026 11:20 PM - PR NewsWire
Form 4 HALOZYME THERAPEUTICS, For: Sep 16 Filed by: Posard Matthew L.
September 17, 2026 5:20 PM - SEC Filing
Form 144 HALOZYME THERAPEUTICS, Filed by: Posard Matthew L.
September 16, 2026 4:41 PM - SEC Filing
Form 8-K HALOZYME THERAPEUTICS, For: Sep 16
September 16, 2026 4:32 PM - SEC Filing
Halozyme proposes $1.05 billion convertible notes offering
September 16, 2026 4:30 PM - StreetInsider
Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033
September 16, 2026 4:30 PM - PR NewsWire
Form 4 HALOZYME THERAPEUTICS, For: Sep 09 Filed by: Torley Helen
September 11, 2026 8:35 PM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)
September 3, 2026 6:58 AM - StreetInsider
Form 3 HALOZYME THERAPEUTICS, For: Aug 14 Filed by: Appelhans Dannielle
August 21, 2026 4:55 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: Aug 17 Filed by: Torley Helen
August 19, 2026 8:01 PM - SEC Filing
Form 8-K HALOZYME THERAPEUTICS, For: Aug 14
August 18, 2026 4:04 PM - SEC Filing
Halozyme adds biotech executive Appelhans to its board
August 18, 2026 4:01 PM - StreetInsider
Halozyme Appoints Dannielle Appelhans to its Board of Directors
August 18, 2026 4:01 PM - PR NewsWire
H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)
August 18, 2026 6:38 AM - StreetInsider
Form 144 HALOZYME THERAPEUTICS, Filed by: Torley Helen
August 17, 2026 5:16 PM - SEC Filing
Form 144 HALOZYME THERAPEUTICS, Filed by: Caudill Cortney
August 11, 2026 5:58 PM - SEC Filing
Form 4 HALOZYME THERAPEUTICS, For: Aug 10 Filed by: Connaughton Bernadette
August 11, 2026 5:44 PM - SEC Filing
Form 144 HALOZYME THERAPEUTICS, Filed by: Connaughton Bernadette
August 10, 2026 4:34 PM - SEC Filing
Halozyme Therapeutics (HALO) PT Raised to $105 at TD Cowen
August 7, 2026 8:52 AM - StreetInsider
Halozyme Therapeutics (HALO) PT Raised to $95 at Wells Fargo
August 7, 2026 8:19 AM - StreetInsider
Halozyme Therapeutics (HALO) PT Raised to $93 at Citizens on Royalty Revenue Growth
August 7, 2026 7:32 AM - StreetInsider
Leerink Upgrades Halozyme Therapeutics (HALO) to Outperform
August 7, 2026 7:02 AM - StreetInsider
Halozyme Therapeutics (HALO) Tops Q2 EPS by 47c; raises guidance
August 6, 2026 4:30 PM - StreetInsider
Form 10-Q HALOZYME THERAPEUTICS, For: Jun 30
August 6, 2026 4:16 PM - SEC Filing
Form 8-K HALOZYME THERAPEUTICS, For: Aug 06
August 6, 2026 4:12 PM - SEC Filing
HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE
August 6, 2026 4:01 PM - PR NewsWire
Halozyme to Report Second Quarter 2026 Financial and Operating Results
July 23, 2026 8:30 AM - PR NewsWire
Full Article List
